Andere talen Pacira BioSciences, Inc.

Aandelen

PCRX

US6951271005

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
26,33 ^USD	+3,25%		+0,30%	-21,96%

13/03	Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
13/03	Pacira BioSciences zegt dat de Amerikaanse FDA het kandidaat-therapeuticum RMAT heeft toegekend aan knieartrose	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Los bancos occidentales advierten de los riesgos del plan de la UE para usar los activos rusos	22/03
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)	20/03
Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	13/03
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis	13/03
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	13/03
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	13/03
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee	13/03
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing	08/03
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference	06/03
Pacira BioSciences' Shares Rise After Company Posts Higher Q4 Non-GAAP Net Income, Revenue	29/02
Pacira: Q4 Earnings Snapshot	29/02
Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02
Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024	29/02
Pacira BioSciences, Inc. Provides Earnings Guidance for the Year 2024	29/02
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q4 Revenue $181.2M, vs. Street Est of $180.9M	29/02
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q4 EPS $0.89, vs. Street Est of $0.85	29/02
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results	29/02
North American Morning Briefing : Fed's Preferred -2-	29/02
Pacira to Report 2023 Financial Results on Thursday February 29, 2024	22/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Pacira BioSciences, Inc.

Aandelen

PCRX

US6951271005

Andere talen

Filters